Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial

被引：0
|
作者：
Krempf, M. [1 ]
Astrup, A. [2 ]
le Roux, C. [3 ]
Fujioka, K. [4 ]
Greenway, F. [5 ]
Halpern, A. [6 ]
Lau, D. C. W. [7 ]
Violante Ortiz, R. [8 ]
Wilding, J. P. H. [9 ]
Jensen, C. B. [10 ]
Lillleore, S. K. [10 ]
Pi-Sunyer, X. [11 ]
机构：
[1] CHRU Nantes, Clin Endocrinol, Nantes, France
[2] Univ Copenhagen, DK-1168 Copenhagen, Denmark
[3] Univ Coll Dublin, Dublin, Ireland
[4] Scripps Clin, La Jolla, CA USA
[5] Louisiana State Univ, Baton Rouge, LA 70803 USA
[6] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil
[7] Univ Calgary, Calgary, AB T2N 1N4, Canada
[8] Inst Mexicano Seguro Social, Ciudad Madero, Mexico
[9] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[10] Novo Nordisk AS, Soborg, Denmark
[11] Columbia Univ, New York, NY USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
903
引用
收藏
页码：S368 / S368
页数：1
相关论文
共 50 条
  • [31] Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria
    Blackman, A.
    Foster, G.
    Zammit, G.
    Rosenberg, R.
    Aronne, L.
    Wadden, T.
    Claudius, B.
    Jensen, C.
    Mignot, E.
    SLEEP MEDICINE, 2015, 16 : S24 - S24
  • [32] IMPACT OF WEIGHT LOSS ON PATIENT-REPORTED OUTCOMES IN THE SCALE OBESITY AND PREDIABETES TRIAL OF LIRAGLUTIDE 3.0 MG AS ADJUNCT TO A DIET AND EXERCISE (D&E) PROGRAMME
    Kolotkin, R. L.
    Meincke, H. J.
    Manning, L. S.
    Bjorner, J. B.
    VALUE IN HEALTH, 2015, 18 (07) : A674 - A675
  • [33] Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
    Kosiborod, Mikhail N.
    Bhatta, Meena
    Davies, Melanie
    Deanfield, John E.
    Garvey, W. Timothy
    Khalid, Usman
    Kushner, Robert
    Rubino, Domenica M.
    Zeuthen, Niels
    Verma, Subodh
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 468 - 478
  • [34] The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults
    Mhurchu, CN
    Poppitt, SD
    McGill, AT
    Leahy, FE
    Bennett, DA
    Lin, RB
    Ormrod, D
    Ward, L
    Strik, C
    Rodgers, A
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (09) : 1149 - 1156
  • [35] The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults
    C Ni Mhurchu
    S D Poppitt
    A-T McGill
    F E Leahy
    D A Bennett
    R B Lin
    D Ormrod
    L Ward
    C Strik
    A Rodgers
    International Journal of Obesity, 2004, 28 : 1149 - 1156
  • [36] Rimonabant Reduces Body Weight and Improves Cardiovascular and Metabolic Risk Factors in an Obese Asian Population: The RIO ASIA Trial
    Ho, Low Tone
    Pan, Changyu
    Yoo, HyungJoon
    OBESITY, 2008, 16 : S237 - S238
  • [37] Effects of a weight management program delivered by social media on weight and metabolic syndrome risk factors in overweight and obese adults: A randomised controlled trial
    Jane, Monica
    Hagger, Martin
    Foster, Jonathan
    Ho, Suleen
    Kane, Robert
    Pal, Sebely
    PLOS ONE, 2017, 12 (06):
  • [38] Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin trial
    Mingrone, G.
    Garvey, T.
    Birkenfeld, A. L.
    Dicker, D.
    Pedersen, S. D.
    Satylganova, A.
    Skovgaard, D. C.
    Sugimoto, D.
    Zeuthen, N.
    Mosenzon, O.
    DIABETOLOGIA, 2019, 62 : S278 - S278
  • [39] Association between overweight/obesity perception, actual body weight and cardiometabolic risk among healthy Ghanaian adults
    Bawah, Abdul -Malik
    Reginald, Annan
    Abdul-Rahman, Haadi
    HUMAN NUTRITION & METABOLISM, 2024, 36
  • [40] Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis
    Hankosky, Emily R.
    Wang, Hui
    Neff, Lisa M.
    Kan, Hong
    Wang, Fangyu
    Ahmad, Nadia N.
    Griffin, Ryan
    Stefanski, Adam
    Garvey, W. Timothy
    DIABETES OBESITY & METABOLISM, 2024, 26 (01): : 319 - 328
12345